base editing

Neville Sanjana explored noncoding genomic regions by combining pooled CRISPR screening and single cell sequencing.

A risk-benefit analysis of gene editing tools in stem cells revealed that base and prime editing carry vulnerabilities similar to those of CRISPR-Cas9, but at a reduced rate. 

Editing epitopes expressed on the surfaces of transplanted hematopoietic stem cells renders them resistant to AML treatments without affecting their critical functions.

Researchers leave no stone unturned in the search for a spinal muscular atrophy treatment strategy that uses base editing.

In a bid to address safety concerns about immune reactions during treatment with CRISPR-based therapeutics, a new technique speeds up how quickly the body destroys the DNA-cutting enzyme Cas9.

A biotech startup called Tessera Therapeutics has made a splash with its claims about the trademarked technology. Is the excitement justified?

Researchers turned to base editors to correct mutations causing the rare genetic disease Fanconi anemia without inducing double-strand DNA breaks.

The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.

RNA editing has been in DNA editing’s shadow for nearly a decade, but recent investments in the technology could bring it into the limelight.

An enzyme pulled from toxic bacteria can enter the organelle and perform single-nucleotide DNA swaps.

In demonstrations in cell lines, the technique has a similar efficacy to CRISPR-Cas9, but fewer off-target effects.

A new study indicates that the modified CRISPR-Cas9 technology will need to be further refined before it can safely be used for research and therapeutic applications.

Adenine editing enzymes have been adapted for use in plants.

Adenine editing enzymes have been adapted for use in plants.

Separate proof-of-concept studies report success against two inherited diseases.